|
|
| |
|
| |
GPEx® Advantage: The Versatile
Solution |
 |
| |
|
| |
|
| |
Multigenic Applications |
| |
|
| |
Bicistronic GPEx® Retrovector |
|
| |
 |
| |
|
| |
GPEx® is ideal for multigenic gene expression
applications:
- Antibody heavy chain and light chain co-expression
- A receptor, co-expressed with a secreted surrogate
- A protein, co-expressed with its processing enzyme
GPEx® has several key advantages in bicistronic (and
multicistronic) applications. Because the two genes are
carried and inserted by a single retrovector, the need
for multiple
selectable markers is avoided. Further, the co-expression
of the genes ensures stoichiometrically desirable ratios
of the
gene products for optimal expression and activity, and
higher yields in production and purification. |
| |
|
| |
Antibody Production |
| |
The GPEx® system has been designed specifically
for optimal expression of virtually any IgG antibody. The
system allows full-length antibodies of Fab fragments, chimeric
antibodies, antibody fusions, single-chain antibodies and variable
regions identified from antibody screening protocols to be inserted
into the GPEx® retrovectors for cell line creation and
subsequent antibody production.
Backbone vectors containing the gamma constant region for human
IgG1, IgG2, IgG3, or IgG4 and light chain kappa or lambda constant
regions allow fusion of DNA sequence encoding IgG variable regions
to any constant regions in the Bicistronic GPEx® Retrovector. These
constant regions can be mixed and matched to produce any IgG
molecule desired. |
| |
|
| |
Splice Variant Analysis |
|
| |
 |
| |
|
| |
Most genes carry introns - non-coding sequences
between coding regions or exons - that are generally spliced
out of mRNA prior to its translation into proteins. Some studies
suggest, however, that for up to 30% of genes, alternative splicing
occurs, such as intron retention or exon skipping, extension
or truncation. These variants are known as splice variants and
provide a mechanism whereby one gene can produce several related
but distinct proteins, some of which may be therapeutically relevant.
GPEx® enables production of retrovectors carrying discrete
splice variants, leading to cell lines that produce proteins
specific for each splice variant.
|
| |
|
|
